natgillin/translations-raw huggingface dataset:
Plasma concentrations of 9-cis-retinoic acid were evaluated during clinical studies in patients with cutaneous lesions of AIDS-related KS after repeated multiple-daily dose application of Panretin gel for up to 60 weeks. 
V kliničnih študijah z bolniki s kožnimi lezijami, ki so nastale zaradi KS povezanega z AIDS, so določili koncentracijo 9-cis-retinoidne kisline v plazmi, in sicer po ponavljajoči se večkratni dnevni aplikaciji zdravila Panretin gel za čas do 60 dni.
The side effects are most likely to appear at the site where Panretin was applied and typically begins as redness. 
Neželeni učinki se večinoma pojavijo na delih kože, na katere ste nanesli zdravilo Panretin gel ter se običajno začnejo s pordelostjo kože.
Name and address of the manufacturer responsible for batch release 
Ime in naslov izdelovalca, odgovornega za sproščanje serije Eisai Manufacturing Limited
There were no biologically relevant haematology differences or serum chemistry differences after the 14-day period. 
LDL v serumu je bil zvišan tako pri skupinah moških kot žensk na 29. dan. Ni bilo biološko relevantnih hematoloških sprememb ali kemičnih sprememb seruma v obdobju po 14 dneh.
Bleeding 
Krvavenje
This dose in rabbits resulted in plasma concentrations more than 60 times the highest observed plasma concentration in patients with KS following topical application of Panretin gel. 
Ta odmerek je pri kuncih povzročil 60-krat višjo koncentracijo v plazmi v primerjavi z najvišjo opaženo koncentracijo v plazmi pri bolnikih s KS po lokalni aplikaciji zdravila Panretin gel.
Sometimes it is necessary to interrupt treatment, your doctor will inform you about this. 
Včasih pa je potrebno zdravljenje prekiniti.
Vehicle N=134 
Vehikel N=134
Panretin gel can be expected to have local therapeutic effects only and it has no role in the prevention or treatment of visceral KS. 
Zdravilo Panretin gel nima vloge pri preprečevanju ali zdravljenju visceralnega KS.
In rabbits, alitretinoin was shown to be teratogenic at a dose which resulted in plasma concentrations about 60 times the highest observed plasma concentration in male patients with KS following topical application of the gel. 
Pri kuncih se je alitretinoin pokazal kot teratogen pri odmerkih, pri katerih je bila koncentracija v plazmi 60-krat višja od najvišje opažene koncentracije v plazmi pri moških bolnikih po lokalni uporabi gela.
However, the mutagenic potential has been evaluated, and alitretinoin has tested negative in the Ames test, the in vivo mouse micronucleus assay, the chromosomal aberration test in human lymphocytes, and the CHO cell mutation test. 
Analizirali so mutageni potencial alitretinoina, ki se je v Amesovem testu, in vitro mikronukleus testu pri miših, testu kromosomske aberacije pri človeških limfocitih ter CHO testu o mutaciji celic, izkazal kot negativen.
AIDSrelated Kaposi's sarcoma is infrequent in this population. 
Kaposijev sarkom kot posledica AIDS je redek pojav pri tej skupini bolnikov.
- A mild soap is recommended when bathing or showering. 
- Za kopanje ali prhanje priporočamo uporabo blagega mila.
Adverse events associated with the use of Panretin gel in AIDS-related KS occurred almost exclusively at the site of application. 
Neželeni učinki, povezani z uporabo zdravila Panretin gel pri KS, ki je posledica AIDS, so se domala vedno pojavili samo na mestu nanosa.
Table 2 Adjustment guidelines for treatment-limiting toxicity LOCAL DERMAL IRRITATION 
Razpredelnica 2 Smernice za prilagoditev odmerjanja pri toksičnosti, ki omejuje zdravljenje LOKALNO DRAŽENJE KOŽE (opredeljeno po razpredelnici 1)
Vehicle (N=134) 
Vehikel (N=134)
Pharmacokinetic studies indicate that the range and frequency of detection of quantifiable 9-cis-retinoic acid plasma concentrations in patients with KS after application of the medicinal product were comparable to the range and frequency of detection of quantifiable plasma concentrations of circulating, naturally-occurring 9-cis-retinoic acid in untreated individuals (see section 5.2). 
S farmakokinetičnimi raziskavami so ugotovili, da sta obseg in pogostost odkritja merljive koncentracije 9-cis-retinoidne kisline v plazmi pri KS bolnikih po nanosu zdravila primerljivi z obsegom in pogostostjo merljive koncentracije 9-cis-retinoidne kisline v obtoku v plazmi, ki se naravno pojavi pri nezdravljenih posameznikih (glejte poglavje 5.2).
Skin ulcer, Serous drainage, Exfoliative dermatitis (flaking, peeling, desquamation, exfoliation), Skin discoloration (brown discoloration, surrounding hyperpigmentation, paler), Dry skin 
kožne razjede, izločanje serozne tekočine, eksfoliativni dermatitis (luščenje kože, lupljenje, deskvamacija, eksfoliacija), sprememba barve kože (sprememba barve v rjavo, obrobna hiperpigmentacija, bledica kože), suha koža celulitis, vezikularni izpuščaj, makulopapularni izpuščaj, alergijska reakcija
Adverse events include verbatim terms in parentheses. 
V oklepajih so navedbe za neželene učinke z dobesednimi izrazi.
- Avoid scratching the treated areas. 
- Ne praskajte se po zdravljenih delih kože.
Common (can occur in less than 1 in 10 but in more than 1 in 100 patients treated): Flaking, peeling, dry skin 
Pogosto (ki se lahko pojavijo pri manj kot enem od 10, toda pri več kot enem od 100 zdravljenih bolnikov):
Skin disorder (cracking, scab, crusting, excoriation, drainage, oozing), Rash (erythema, redness, scaling, irritation, dermatitis), Pruritus (itching, pruritus) 
Bolezni kože in podkožja kožne motnje (pokanje kože, kraste, krastavost, odrgnine, izločanje tekočine, izcedki), izpuščaji (eritem, pordelost, luskavica, draženje, vnetje kože), pruritus (srbenje, pruritus)
Alitretinoin may cause harm to the foetus. 
Alitretinoin lahko škodljivo vpliva na razvoj zarodka.
It is not known whether this medicinal product is excreted in human milk. 
Ni znano, ali se alitretinoin izloča preko materinega mleka.
You need to avoid applying the gel to the healthy skin around the lesion. 
Preprečite nanos gela na zdravo kožo okoli lezije.
It is supplied in a multi-use 60 g epoxy-lined aluminium tube. 
Je na razpolago v aluminijasti tubi z epoksi prevleko za večkratno uporabo.
Progressive Disease % 
Progresivna bolezen % 14,9
Panretin gel is supplied in a multi-use 60 g epoxy-lined aluminium tube. 
Zdravilo Panretin gel je na razpolago v aluminijasti tubi z epoksi prevleko za večkratno uporabo.
Table 5 Index/indicator lesion 1 responses within patients during the first 12 weeks on study in initial blinded phase Patients with given number of index/indicator lesion responses (CCR or PR) Study 1 
Bolniki z dano številko indeksa/indikatorja za odziv lezij (CCR ali PR) Študija 1
Apply Panretin to your KS lesions using a clean finger. 
S čistim prstom nanesite zdravilo Panretin gel na KS lezije.
What is in this leaflet: 
Kaj vsebuj navodilo
The dermal toxicity typically begins as erythema; with continued application of Panretin gel erythema may increase and oedema may develop. 
Pri nadaljnji uporabi zdravila Panretin gel se lahko eritem poveča in se razvije edem.
In this latter group, the range and frequency of detection of quantifiable 9-cis-retinoic acid plasma concentrations in patients with KS after application of the medicinal product were comparable to the range and frequency of detection of quantifiable plasma concentrations of circulating, naturally-occurring 9-cis-retinoic acid in untreated individuals. 
V zadnji sta bila obseg in pogostost odkritja merljive koncentracije 9-cis-retinoidne kisline v plazmi pri bolnikih s KS po dajanju zdravila primerljiva z obsegom in pogostostjo odkritja merljive koncentracije 9-cis-retinoidne kisline v plazmi, ki se naravno pojavlja pri nezdravljenih posameznikih.
The patient response rate was evaluated using the AIDS Clinical Trials Group (ACTG) criteria for lesion response in KS. Study 1 included an open-label phase, in which patients themselves elected to enroll. 
Stopnjo odziva pri bolnikih so analiziraliz merili za odziv lezij pri KS Skupine kliničnih študij za AIDS (ACTG).
- Avoid showering, bathing, or swimming for at least three hours after any application. 
- Po vsakem nanosu se morate za najmanj tri ure odpovedati prhanju, kopanju in plavanju.
It is recommended that you should not eat more vitamin A in your diet than the amount suggested by your doctor. 
Uporaba zdravila Panretin skupaj s hrano in pijačo Priporočamo, da ne zaužijete količine vitamina A skupaj s hrano, ki bi bila večja od tiste, ki vam jo je svetoval zdravnik.
No gross malformations were observed following oral administration to rabbits of doses 12 times the human topical dose (which resulted in plasma concentrations 60 times the highest observed plasma concentration in patients with KS following topical application of the gel). 
Neposredno po peroralnem dajanju kuncem z 12-krat večjim odmerkom v primerjavi z lokalnim odmerkom pri ljudeh (ki je povzročil 60-krat višjo koncentracijo v plazmi v primerjavi z najvišjo opaženo koncentracijo v plazmi pri bolnikih s KS po lokalni uporabi gela) niso opazili močnih nepravilnosti.
- Women of child-bearing age must use an effective method of birth control while using Panretin, and for one month after finishing treatment. 
- Plodne ženske si morajo tako v času uporabe kot tudi en mesec po prenehanju uporabe zdravila Panretin gel zagotoviti učinkovito kontracepcijsko sredstvo.
A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE 
A IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
Care should be taken not to bring the neonate into skin contact with areas to which Panretin has been recently applied. 
Posebna pozornost je potrebna, da novorojenec s svojo kožo ne pride v stik s predeli kože bolnika(-ce), na katere je bilo pred kratkim naneseno zdravilo Panretin gel.
What Panretin contains - The active substance is alitretinoin. 
- Učinkovina je alitretinoin.
1 = Mild 
1 = Blago
NUMBER(S) IN THE COMMUNITY REGISTER OF MEDICINAL PRODUCTS 
POSTOPEK IN POT(I) UPORABE ZDRAVILA
• You may need to reduce the number of daily applications, or stop using Panretin for a short while, if you develop unwanted skin effects. 
• Če se razvijejo neželeni kožni znaki morate morda zmanjšati število dnevnih nanosov zdravila
What Panretin looks like and contents of the pack Panretin is a clear yellow gel. 
Zdravilo Panretin je prozoren gel rumene barve.
The use of other topical products on Panretin treated KS lesions should be avoided. 
Na KS lezijah, zdravljenih z zdravilom Panretin, se je treba izogibati uporabi drugih izdelkov za lokalno uporabo.
How to store Panretin 
Shranjevanje zdravila Panretin
Clear yellow gel. 
Gel Prozoren, rumen gel
(see section 5.3). 
navedeno v poglavju 6.1.
However, patients must be cautioned to minimise exposure of treated areas to sunlight or other ultraviolet (UV) light. 
V kliničnih raziskavah sicer niso poročali o občutljivosti za svetlobo v povezavi z uporabo zdravila Panretin gel, vendar je bolnike potrebno opozoriti, naj zmanjšajo izpostavljenost zdravljenih predelov kože sončni svetlobi ali drugi ultravijolični (UV) svetlobi (glejte poglavje 5.3)
The use of other topical products on treated KS lesions should be avoided. 
Izogibajte se nanosu drugih lokalnih pripravkov na zdravljene KS lezije.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING 
Izgled zdravila Panretin in vsebina pakiranja
Hydroxypropylcellulose Butylhydroxytoluene 
6.1 Seznam pomožnih snovi etanol makrogol 400 hidroksopropilceluloza butilhidroksitoluen
Vascular disorders 
Otekle bezgavke
Alitretinoin was shown to have a weak potential to be a photo-irritant based on histidine and photoprotein binding. 
Zaradi vezanja na histidin in fotoprotein ima alitretinoin le nizek potencial za draženje zaradi svetlobe.
Your doctor can give you more information. 
O tem vas bo obvestil zdravnik.
EXPIRY DATE 
Mosquito Way
Care must be taken to avoid application of the gel to normal skin surrounding the lesions. 
Posebna pozornost je potrebna pri nanosu gela, saj se le-ta ne sme nanesti na zdravo kožo ob leziji.
- Mineral oil may be used between Panretin applications in order to help prevent excessive dryness or itching. 
- Med posameznim nanašanjem zdravila Panretin gel lahko uporabite mineralno olje.
This overview was last updated in November 2018. 
Povzetek je bil nazadnje posodobljen novembra 2018.
Further information on Isemid can be found on the Agency's website: ema.europa.eu/ medicines/veterinary/EPAR/isemid. 
Nadaljnje informacije o zdravilu Isemid so na voljo na spletni strani agencije: ema.europa.eu/ medicines/veterinary/EPAR/isemid.
This medicine may also cause hypersensitivity (allergic) reactions. 
To zdravilo lahko povzroči tudi preobčutljivostne (alergijske) reakcije.
The dose is then reduced and adjusted according the dog's response. 
Odmerek se nato zmanjša in prilagodi glede na odziv psa.
Isemid received a marketing authorisation valid throughout the EU on 09/01/2019. 
Zdravilo Isemid je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 09/01/2019.
The European Medicines Agency decided that Isemid's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Isemid večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Other information about Isemid 
Druge informacije o zdravilu Isemid
The tablet can be given with food or directly into the mouth if the dog does not take it easily. 
Tableto se lahko daje skupaj s hrano ali neposredno v usta, če jo pes vzame s težavo.
It works by increasing the loss of water and salt in the urine. 
Deluje tako, da poveča izločanje vode in soli z urinom.
It is given once daily and the starting dose depends on bodyweight. 
Daje se enkrat na dan, začetni odmerek pa je odvisen od telesne mase.
Isemid must not be given at the same time as other diuretics which work in the same way as torasemide. 
Zdravilo Isemid se ne sme dajati hkrati z drugimi diuretiki, ki delujejo na enak način kot torasemid.
The usual dose is 0.13 to 0.25 mg torasemide per kg bodyweight once daily. 
Običajni odmerek je od 0,13 do 0,25 mg torasemida na kilogram telesne mase enkrat na dan.
This may be increased for up to 5 days to a maximum of 0.4 mg per kg bodyweight once daily in dogs with moderate to severe fluid retention in the lungs. 
To se lahko poveča za največ 5 dni do največ 0,4 mg na kilogram telesne mase enkrat na dan pri psih z zmernim do hudim zastajanjem tekočine v pljučih.
The most common side effects with Isemid (which may affect more than 1 in 10 animals) are poor function of the kidneys, alterations in blood tests measuring kidney function, haemoconcentration (increase in the concentration of red blood cells circulating in the blood), and changes in electrolyte (salt) levels (chloride, sodium, potassium, phosphorus, magnesium and calcium). 
Najpogostejši neželeni učinki zdravila Isemid (ki lahko prizadenejo več kot 1 od 10 živali) so slabo delovanje ledvic, spremembe krvnih testov merjenja delovanja ledvic, hemokoncentracija (povečanje koncentracije rdečih krvnih celic v obtoku v krvi) in spremembe ravni elektrolitov (soli) (klorida, natrija, kalija, fosforja, magnezija in kalcija).
Any part-used tablets should be returned to the blister pack and then to the original carton to keep them out of the reach of children. 
Vse delno uporabljene tablete je treba vrniti v pretisni omot, nato pa v originalno embalažo, da se hranijo zunaj dosega otrok.
What is Isemid and what is it used for? 
Kaj je zdravilo Isemid in za kaj se uporablja?
Why is Isemid authorised in the EU? 
Zakaj je zdravilo Isemid odobreno v EU?
Congestive heart failure is a condition when the heart cannot pump enough blood around the body. 
Kongestivno srčno popuščanje je stanje, pri katerem telo ne more črpati dovolj krvi po telesu.
This can lead to exercise intolerance (inability to carry out physical activity), difficulty breathing and fluid retention. 
To lahko povzroči intoleranco za telesno dejavnost (nezmožnost za fizične aktivnosti), težave z dihanjem in zastajanje vode v telesu.
Isemid (torasemide) EMA/790616/2018 
Isemid (torasemid) EMA/15628/2019
The main measure of effectiveness was a reduction in scores for lung fluid and cough (both are signs of congestive heart failure) after 14 days of treatment and no worsening of difficulty in breathing or exercise intolerance scores. 
Glavno merilo učinkovitosti je bilo zmanjšanje števila primerov tekočine v pljučih in kašlja (oba sta znamenje kongestivnega srčnega popuščanja) po 14 dneh zdravljenja in brez poslabšanja težav pri dihanju ali pri oceni intolerance za telesno dejavnost.
What benefits of Isemid have been shown in studies? 
Kakšne koristi je zdravilo Isemid izkazalo v študijah?
People who are hypersensitive to torasemide, sulfonamides or to any of the other ingredients in Isemid should avoid contact with the medicine. 
Osebe, ki so preobčutljive za torasemid, sulfonamide ali katero koli drugo sestavino zdravila Isemid, se morajo izogibati stiku z njim.
What are the risks associated with Isemid? 
Kakšna tveganja so povezana z zdravilom Isemid?
In a field study involving 321 dogs with congestive heart failure, treatment with Isemid was compared with another established diuretic medicine, furosemide. 
V terenski študiji, ki je zajela 321 psov s kongestivnim srčnim popuščanjem, so zdravljenje z zdravilom Isemid primerjali z drugim uveljavljenim diuretikom, furosemidom.
An overview of Isemid and why it is authorised in the EU 
Pregled zdravila Isemid in zakaj je odobreno v EU
This decreases the overall blood volume, reducing the effort needed for the heart to pump blood and thereby improving its function. 
S tem se zmanjša skupna krvna prostornina in posledično napor srca, potreben za črpanje krvi, kar izboljša njegovo delovanje.
Isemid is a veterinary medicine used to treat signs related to congestive heart failure in dogs. 
Isemid je veterinarsko zdravilo, ki se uporablja za zdravljenje znakov, povezanih s kongestivnim srčnim popuščanjem pri psih.
For more information about using Isemid, see the package leaflet or contact your veterinarian or pharmacist. 
Za več informacij glede uporabe zdravila Isemid glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
Isemid must not be given in cases of kidney failure, dehydration, a decrease in circulating blood volume or low blood pressure. 
Zdravilo Isemid se ne sme dajati v primeru odpovedi ledvic, dehidracije, zmanjšanja prostornine krvi v obtoku ali nizkega krvnega tlaka.
Isemid to be as least as effective as furosemide for the treatment of signs related to congestive heart failure with 74% of dogs in each group being successfully treated. 
furosemid za zdravljenje znakov, povezanih s kongestivnim srčnim popuščanjem, saj je bilo uspešno zdravljenih 74 % psov v vsaki skupini.
Isemid is available as tablets and can only be obtained with a prescription. 
Zdravilo Isemid je na voljo v obliki tablet, predpisovanje in izdaja zdravila pa je le na recept.
If the product is accidentally swallowed by a person, particularly by a child, the advice of a doctor should be sought immediately and the package leaflet or label shown to the doctor. 
Če človek, zlasti otrok, zdravilo nenamerno zaužije, se je treba nemudoma posvetovati z zdravnikom in mu pokazati navodilo za uporabo ali nalepko.
For the full list of side effects and restrictions of Isemid, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Isemid glejte navodilo za uporabo.
Isemid may increase urination, and lead to thirst, gut disturbances, low blood pressure and dehydration if ingested. 
Če se zdravilo Isemid zaužije, lahko poveča uriniranje in povzroči žejo, motnje prebavil, nizek krvni tlak in dehidracijo.
If symptoms of allergy occur, the advice of a doctor should be sought immediately and the package leaflet or label shown to the doctor. 
Če se na koži pojavijo simptomi alergije, se je treba nemudoma posvetovati z zdravnikom in mu pokazati navodilo za uporabo ali nalepko.
Isemid contains the active substance torasemide. 
Zdravilo Isemid vsebuje učinkovino torasemid.
How is Isemid used? 
Kako se zdravilo Isemid uporablja?
How does Isemid work? 
Kako zdravilo Isemid deluje?
If you notice any of the above symptoms: 
Če opazite katerega od naštetih simptomov:
It is usually given into your arm over about 30 minutes. 
Po navadi se daje v roko v trajanju približno 30 minut.
Risk of bacterial infections 
Tveganje za bakterijske okužbe
Eligible patients were not to have had >3 days of prior antiviral treatment. 
Primerni bolniki niso smeli imeti > 3 dni predhodnega protivirusnega zdravljenja.
• confused thinking 
• zmedeno razmišljanje,
It is used when other flu treatments are not suitable. 
Uporablja se, kadar druga zdravila za gripo niso primerna.
Your dose may be increased or decreased depending on how well you respond to treatment. 
Zdravnik vam lahko odmerek poveča ali zmanjša glede na to, kako dobro se odzovete na zdravljenje.
Influenza can be associated with a variety of neurological and behavioural symptoms. 
Gripa je lahko povezana z različnimi nevrološkimi in vedenjskimi simptomi.
The initial 5 day treatment course could be extended for up to 5 additional days if clinical symptoms or patient characteristics warranted further treatment. 
Uvodnih 5 dni ciklusa zdravljenja je bilo mogoče podaljšati za do 5 dodatnih dni, če so klinični simptomi ali bolnikove značilnosti zahtevali nadaljnje zdravljenje.
• Each vial is for single use only; once the seal has been broken, the remaining volume must be discarded. 
• Posamezna viala je le za enkratno uporabo; ko je zapora pretrgana, je treba preostalo količino zavreči.
• if you are allergic to zanamivir or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na zanamivir ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
This means that for scientific reasons it has not been possible to get complete information on this medicine. 
To pomeni, da iz znanstvenih razlogov ni bilo mogoče pridobiti vseh podatkov o zdravilu.
Therefore, patients should be closely monitored for behavioural changes and the benefits and risks of continuing treatment should be carefully evaluated for each patient (see section 4.8). 
Zato je treba bolnike natančno nadzirati glede vedenjskih sprememb, koristi in tveganja nadaljevanja zdravljenja pa je treba pri vsakem bolniku skrbno oceniti (glejte poglavje 4.8).
➔ Tell a doctor or nurse immediately. 
Takoj obvestite zdravnika ali medicinsko sestro.
If your kidneys are not working as well as they should, your doctor will decide on the reduced dose for you. 
Če vam ledvice ne delujejo, kot bi morale, se bo zdravnik odločil, kolikšen naj bo vaš zmanjšani odmerek.
Phase III study in patients with complicated influenza 
Študija III. faze pri bolnikih z zapleteno gripo
Dectova should be used in accordance with official guidance. 
Zdravilo Dectova je treba uporabljati v skladu z uradnimi smernicami.
Contact your doctor or nurse straight away if you notice any of the following serious side effects: 
Nemudoma se posvetujte z zdravnikom ali medicinsko sestro, če opazite katerega od naslednjih resnih neželenih učinkov:
Dectova must not be mixed with other medicinal products except those mentioned in section 6.6. 
Zdravila Dectova se ne sme mešati z drugimi zdravili razen s tistimi, ki so omenjena v poglavju 6.6.
The primary analysis was performed on the Influenza Positive Population (IPP) comprised of 488 patients. 
Primarno analizo so izvedli v populaciji, pozitivni za gripo, ki je obsegala 488 bolnikov.
Date of first authorisation: 26 April 2019 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 26. april 2019
The median patient age was 57 years and 35% (218/615) of patients were ≥65 years, of which 17% (n=103) were 65 to <75; 14% (n=84) were 75 to <85, and 5% (n=31) were ≥85 years of age. 
Mediana starost bolnikov je bila 57 let in 35 % (218/615) bolnikov je bilo starih ≥ 65 let, od katerih je bilo 17 % (n = 103) starih 65 do < 75 let, 14 % (n = 84) 75 do < 85 let in 5 % (n = 31) ≥ 85 let.
6 months to < 6 years 
6 mesecev do < 6 let